RR-A2 is a novel 39-amino acid synthetic peptide representing a first-in-class dual incretin agonist that simultaneously activates multiple metabolic receptors. The peptide features a C20 fatty diacid acyl chain for albumin binding, enabling once-weekly dosing with an approximate 5-day half-life. Unlike balanced dual agonists, RR-A2 demonstrates: - Greater affinity for GIP receptors than other incretin receptors - This "imbalanced" design minimizes certain side effects while maximizing primary pathway engagement At the incretin receptor level, RR-A2 shows biased agonism favoring cAMP generation over β-arrestin recruitment—a unique signaling profile that may enhance efficacy while improving tolerability. - Glucose-dependent insulin secretion through dual incretin effect - Glucagon suppression during hyperglycemic states - Enhanced β-cell function indicators (HOMA2-B improvements) - Improved proinsulin/insulin ratios (β-cell health marker) - Enhanced insulin sensitivity (u
RR-A2: Dual Receptor Agonist Research Guide
An exploration of RR-A2, the first-in-class dual incretin agonist targeting multiple metabolic receptors.